Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Leaps by Bayer
Deal Size : $80.0 million
Deal Type : Series B Financing
Details : The financing will be used to advance NextPoint’s two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 01, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Leaps by Bayer
Deal Size : $80.0 million
Deal Type : Series B Financing
Lead Product(s) : Ulodesine
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Laevoroc Immunology is repurposing the small molecule drug, Ulodesine, originally developed for the treatment of gout, as an oral immuno-oncology agent to initiate graft-versus-leukemia reaction for relapsed cases after allogenic stem cell transplantatio...
Product Name : LR 09
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 07, 2021
Lead Product(s) : Ulodesine
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : CellPoint
Deal Size : Undisclosed
Deal Type : Collaboration
Details : CellPoint and Lonza will collaborate to rapidly develop several T-cell based therapies and utilize the Cocoon® Platform for clinical point-of-care manufacturing.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 23, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : CellPoint
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Ajinomoto Bio-Pharma
Deal Size : Undisclosed
Deal Type : Collaboration
Details : As part of the collaboration and license agreement with Ajinomoto Co., the AJICAP® technology will be used to conjugate Bright Peak’s enhanced cytokines as payloads to certain antibodies, creating novel and proprietary Bright Peak Immunocytokines.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 25, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Ajinomoto Bio-Pharma
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Pelareorep,Atezolizumab
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Oncolytics Biotech
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The phase 1/2 trial, known as GOBLET, will investigate the use of pelareorep, in combination with Roche's anti-PD-L1 checkpoint inhibitor atezolizumab (Tecentriq®), in patients with metastatic pancreatic, metastatic colorectal and advanced anal cancers.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Undisclosed
October 27, 2020
Lead Product(s) : Pelareorep,Atezolizumab
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Oncolytics Biotech
Deal Size : Undisclosed
Deal Type : Collaboration